aTYR PHARMA INC
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 7, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | After market close | – | $-0.14 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | – | $-0.17 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | – | $-0.18 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | $-0.23 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| annualized operating expenses reduction | fourth quarter of 2026 | $13.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements aTYR PHARMA filed with the SEC
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond June 2026 © 2026 aTyr Pharma Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K/A
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Sr. Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
The Evolutionary Intelligence Biotech September 2023 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Director, Investor Relations and Public Affairs
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99.1 to Form 8-K
A New Path to Medicine Company Reception
Other events · EX-99.1 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99.1 to Form 8-K
Director, Investor Relations and Corporate Communications
Results of operations · EX-99.1 to Form 8-K